Cohen Joshua B 4
Accession 0001193125-26-037552
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:05 PM ET
Size
5.2 KB
Accession
0001193125-26-037552
Research Summary
AI-generated summary of this filing
Amylyx CEO Joshua B. Cohen Sells 15,500 Shares
What Happened
Joshua B. Cohen, CEO of Amylyx Pharmaceuticals (AMLX), sold 15,500 shares on February 2, 2026, realizing approximately $227,593. The reported weighted-average sale price was $14.68 per share (individual trade prices ranged $14.510–$14.760). This was a sale (S) tied to tax withholding on vested restricted stock units and was automatic—not an open discretionary sell for investment reasons.
Key Details
- Transaction date: 2026-02-02 (reported on Form 4 filed 2026-02-04).
- Price: weighted average $14.68; trades ranged from $14.510 to $14.760.
- Shares sold: 15,500; proceeds ≈ $227,593.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Footnotes: F1 = sale required to cover tax withholding on vesting RSUs (automatic); F2 = weighted-average price, multiple transactions.
- Timeliness: Filed Feb 4, 2026 for a Feb 2 transaction—no late filing indicated.
Context
Sales to cover tax withholding on vested awards are routine and automatic and do not necessarily indicate a CEO’s view on the company’s prospects. This was not reported as part of a 10b5-1 plan or an opportunistic open-market purchase; it was a tax-withholding disposition related to RSU vesting.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-02$14.68/sh−15,500$227,593→ 3,363,965 total
Footnotes (2)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Signature
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Related Parties
1- filerCIK 0001898644
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 4:05 PM ET
- Size
- 5.2 KB